Overall survival remains unsatisfactory in stage II/III gastric cancer, even after curative surgery and adjuvant chemotherapy. Platelet-derived growth factor receptor-β (PDGFR-β) is associated with the proliferation of cancer cells. The present study therefore investigated the association of PDGFR-β gene expression with patient outcome in 134 stage II/III gastric cancer patients who received adjuvant chemotherapy with S-1. Relative PDGFR-β gene expression was measured in surgical cancer tissue and adjacent normal mucosa specimens by reverse transcription-quantitative polymerase chain reaction. The PDGFR-β gene expression levels were found to be significantly higher in the cancer tissues compared with the adjacent normal mucosa. A high level of PDGFR-β gene expression was associated with a significantly poorer 5-year overall survival rate compared with a low level of PDGFR-β expression. Upon multivariate analysis, PDGFR-β gene expression was found to be an independent predictor of survival. Overall, the study indicates that PDGFR-β overexpression in gastric cancer tissues is a useful independent predictor of outcome in patients with stage II/III gastric cancer who receive adjuvant chemotherapy with S-1.
Introduction
Gastric cancer is the fourth most common cancer globally and the second leading cause of cancer-associated mortality (1) .
Gastrectomy with D2 dissection and progress in chemotherapy have significantly improved survival times in patients with gastric cancer (2, 3) . The standard treatment for stage II/III gastric cancer is curative resection and adjuvant chemotherapy. On the basis of the results of the Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer, patients with stage II/III gastric cancer in Japan usually receive S-1 for 1 year after gastrectomy. However, despite treatment with S-1, the 5-year overall survival rate is 71.7% and thus remains unsatisfactory (4) . Therefore, great hope has been placed on the development of personalized medicine using biomarkers to improve outcomes in stage II/III gastric cancer.
Platelet-derived growth factor receptor-β (PDGFR-β) is a cell surface tyrosine kinase receptor for members of the PDGF family. PDGFR-β is expressed in numerous types of human neoplasms, including gastric cancer (5) (6) (7) . PDGFR-β signaling has been reported to increase tumor cell proliferation in an autocrine manner (8) , and to stimulate angiogenesis (9) , recruit pericytes (8, 10) and regulate interstitial fluid pressure (IFP) in the stroma; PDGFR-β thereby affects the transvascular transport of chemotherapeutic agents in a paracrine manner (11) .
The present study was designed to evaluate the clinical significance of PDGFR-β gene expression in patients with stage II/III gastric cancer who received curative resection followed by adjuvant chemotherapy with S-1.
Materials and methods
Patients and samples. The present study focused on surgically resected specimens of cancer tissue and adjacent normal mucosa obtained from 134 patients with stage II/III gastric cancer who underwent curative surgery without receiving pre-operative chemotherapy or radiotherapy. Tumor stage was evaluated according to the 7th edition of the International Union Against Cancer (UICC)-TNM classification of malignant tumors (12) . The patients post-operatively received adjuvant chemotherapy with S-1. All patients were treated in the Department of Surgery, Yokohama City University (Yokohama, 
Oligonucleotide primers for PDGFR-β cDNA amplification by reverse-transcription polymerase chain reaction (RT-PCR).
The oligonucleotide primers for PDGFR-β were as follows: Sense, 5'-CGT GGC TTT TCT GGT ATC TTT GAG-3' and antisense, 5'-CGT TGA TGG ATG ACA CCT GGAG-3'. β-actin was used as the internal control. The oligonucleotide primers for β-actin were as follows: Sense, 5'-AGT TGC GTT ACA CCC TTT CTT GAC-3' and antisense, 5'-GCT CGC TCC AAC CGA CTGC-3'. Amplification of PDGFR-β was performed for 40 cycles of 10 sec at 95˚C, 10 sec at 58˚C and 20 sec at 72˚C. Amplification of β-actin was performed for 40 cycles of 15 sec at 95˚C, 15 sec at 60˚C and 30 sec at 72˚C. A 10-µl aliquot of each amplified PCR product underwent electrophoresis in a 3% agarose gel containing ethidium bromide.
Immunohistochemical staining. Immunohistochemical studies of PDGFR-β were performed on formalin-fixed, paraffin-embedded surgical specimens obtained from the gastric cancer patients. The section width was specified as 4 µm. The tissue sections were deparaffinized and soaked in 10 mM sodium citrate buffer (pH 6.0) at 121˚C for 15 min to retrieve cell antigens. Blocking was performed twice. First, endogenous peroxidase activity was blocked with 3% hydrogen peroxide solution for 5 min. Next, protein activity was blocked with 5% skimmed milk for 5 min. Subsequent to blocking, the sections were incubated overnight at 4˚C to allow antigen-antibody reactions to occur. Peroxidase-labeled polymer (EnVision+, rabbit; Dako, Glostrup, Denmark) was used to detect signals of the antigen-antibody reactions. All sections were counterstained with hematoxylin. The primary rabbit polyclonal antibodies against PDGFR-β (catalog no., HPA028499; Atlas Antibodies, Stockholm, Sweden) were used at a dilution of 1:100.
RT-quantitative (q)PCR. RT-qPCR was performed using iQ SYBR Green Supermix (Bio-Rad Laboratories, Inc.). PCR was performed in a total volume of 15 µl, which included 0.2 µg cDNA, 0.4 µM of each primer, 7.5 µl iQ SYBR-Green Supermix containing dATP, dCTP, dGTP and dTTP at concentrations of 400 µM each, and 50 U/ml of iTag DNA polymerase. The PCR cycling conditions consisted of 10 min at 95˚C, followed by 40 cycles of denaturation of the cDNA for 10 sec at 95˚C, annealing for 10 sec at 56˚C (60˚C for β-actin) and a primer extension for 20 sec at 72˚C, followed by 10 min at 72˚C. To distinguish specific from non-specific products and primer dimers, melting curve analyses were performed. To evaluate specific mRNA expression in the samples, a standard curve was created for each run, based on three points from human control cDNA (Clontech Laboratories, Inc., CA, USA). The concentrations of each sample were calculated by relating their crossing point to the standard curve. The number of experimental repeats was three times, and the method used for quantitation was relative quantities (iQ5 software version 2.0; Bio-Rad Laboratories, Inc.).
Statistical analysis.
Differences between gene expression levels in the gastric cancer and adjacent normal mucosa samples were compared using the Wilcoxon test. The associations between gene expression and potential explanatory variables, including age, gender, tumor size, histological type, serosal invasion, lymph node metastasis, tumor-node-metastasis (TNM) stage (12) , lymphatic invasion and venous invasion, were evaluated using the χ 2 test. Associations between PDGFR-β gene expression and survival were assessed using the Kaplan-Meier method and were compared by the log-rank test. A Cox proportional-hazards model was used to perform univariate analyses and stepwise multivariate analyses to determine risk factors. All statistical analyses were performed with the Dr. SPSS II program, version 11.0.1 J for Windows (SPSS, Inc., Chicago, IL, USA). Two-sided P-values were calculated, and a difference was considered statistically significant at P<0.05. Data are expressed as median (range).
Results

PDGFR-β mRNA expression in specimens of cancer tissue
and adjacent normal mucosa. PDGFR-β gene expression was examined by RT-PCR, using gastric cancer tissue and normal gastric mucosal tissue obtained from 7 patients (Fig. 1) . The results revealed that PDGFR-β expression was significantly higher in tumor tissue than in normal gastric mucosal tissue. Therefore, PDGFR-β gene expression was examined by RT-qPCR in gastric cancer tissue and normal gastric mucosa in 75 patients for whom samples of both gastric cancer tissue and normal gastric mucosal tissue were available. The mRNA expression levels of PDGFR-β in specimens of cancer tissue and adjacent normal mucosa obtained from 7 patients with gastric cancer were analyzed by RT-PCR (Fig. 1) . PDGFR-β mRNA expression was significantly higher in the cancer tissues than in the paired normal adjacent mucosa. PDGFR-β mRNA expression was confirmed in clinical samples (n=75) by RT-qPCR. Expression levels of the PDGFR-β gene were significantly higher in the cancer tissues compared with the adjacent normal mucosa (P=0.009; Fig. 2) .
Immunohistochemistry of PDGFR-β expression. Expression of PDGFR-β protein was evaluated by immunohistochemical analysis of resected specimens of gastric cancer. Positive staining for PDGFR-β was observed in the tumor stromal cells of the gastric cancer tissue in differentiated and undifferentiated types of gastric cancer (Fig. 3) .
Associations between PDGFR-β mRNA expression levels and clinicopathological features. Expression levels of the PDGFR-β, platelet-derived growth factor receptor-β; TNM, tumor-node-metastasis. 
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PDGFR-β gene were categorized as low or high according to the median value. The associations between gene expression and clinicopathological features were then examined. Expression levels of the PDGFR-β gene were not found to be associated with any clinicopathological variable (Table I) .
Associations between PDGFR-β mRNA expression levels and outcome. The expression levels of the PDGFR-β gene were categorized as low or high according to the median expression value. Overall survival was significantly poorer in the patients with high expression levels (5-year overall survival rate, 58.8%) of the PDGFR-β gene than in those with low expression levels (5-year overall survival rate, 79.4%) (P=0.045; Fig. 4 ). (Table II) .
Discussion
The standard treatment for stage II/III gastric cancer is a curative resection and adjuvant chemotherapy. The overall survival rate of patients with stage II/III gastric cancer remains unsatisfactory, even after curative surgery and adjuvant chemotherapy with S-1 (2-4). Improved risk stratification and personalized medicine based on biomarker analysis will hopefully improve outcomes in stage II/III gastric cancer. The present study therefore focused on PDGFR-β and examined the clinical significance of PDGFR-β expression in patients with stage II/III gastric cancer who received curative surgery and post-operative adjuvant chemotherapy with S-1. The present study examined the expression levels of PDGFR-β mRNA in gastric cancer and adjacent normal mucosa. Studies have previously compared the relative mRNA expression levels of the PDGFR-β gene between various types of cancer tissue and adjacent normal mucosa. Erben et al reported that PDGFR-β mRNA expression is higher in rectal cancer tissue than in normal rectal mucosa (13). Antoniades et al found that PDGF and PDGFR-β mRNA are strongly expressed in lung carcinoma tissue, but not in normal lung tissue (14) . Vrekoussis et al showed that immunohistochemical expression levels of endothelial PDGFR-β are significantly higher in breast cancer tissue than in normal breast tissue (15) , and Guo et al reported that the positive rate of immunohistochemical PDGFR-β expression is significantly higher in gastric carcinoma tissue than in normal gastric mucosa tissue (16) . The present results are consistent with these findings. PDGFR-β mRNA expression levels were significantly higher in 75 specimens of gastric cancer tissue than in the paired adjacent normal mucosa.
The associations between PDGFR-β mRNA expression levels and clinicopathological features in gastric cancer were then evaluated. Kodama et al reported that PDGFR-β expression correlates with lymph node metastasis in gastric cancer (5). Suzuki et al showed that activation of PDGFR-β correlates with the depth of tumor invasion in gastric cancer (17) , and Guo et al reported that PDGFR-β expression positively correlates with the depth of tumor invasion, lymph node metastasis and TNM stage in gastric cancer (16) . By contrast, the expression levels of PDGFR-β mRNA were not associated with any clinicopathological features in the present study.
Finally, the present study assessed the associations between PDGFR-β gene expression levels and outcome in stage II/III gastric cancer after curative resection and adjuvant chemotherapy with S-1. Paulsson et al reported that high stromal PDGFR-β expression significantly correlates with shorter recurrence-free and cancer-specific survival times in various types of breast cancer (18) , while Hägglöf et al showed that stromal PDGFR-β expression predicts cancer-specific survival in various types of prostate cancer (19) . Sato et al (20) reported that PDGFR-β expression is a significant prognostic factor in grade II/III astrocytoma and grade IV glioblastoma. Chen et al (21) found that PDGFR-β overexpression alone is not a significant predictor of either disease-free survival or overall survival, whereas PDGFR-α/PDGFR-β/vascular endothelial growth factor coexpression significantly correlates with poorer disease-free survival and overall survival in patients with stage I-IV hepatocellular carcinoma. By contrast, Shinohara et al reported that the levels of PDGFR-β expression are not a statistically significant predictor of 5-year overall survival in either limited or extensive small-cell lung cancer (22) . The present results showed that high PDGFR-β expression levels were a significant independent predictor of a poorer 5-year overall survival rate in patients with stage II/III gastric cancer after curative resection and post-operative adjuvant chemotherapy with S-1. Upon multivariate Cox proportional hazards Figure 4 . Association between platelet-derived growth factor receptor-β (PDGFR-β) mRNA expression and post-operative survival. Expression levels of the PDGFR-β gene were categorized as low or high according to the median value. The post-operative survival rate was analyzed by the Kaplan-Meier method, and differences in survival rates were assessed by the log-rank test. Overall survival was significantly poorer in patients with high expression levels of the PDGFR-β gene than in those with low expression levels (P= 0.045).
regression analysis, high levels of PDGFR-β gene expression were independently and inversely associated with outcome.
The molecular mechanisms and functional impact of PDGFR-β expression in cancer remain to be fully elucidated. PDGFR-β promotes the proliferation of tumor-associated fibroblasts and neovascular endothelial cells participating in tumor angiogenesis; it also increases IFP, and a higher IFP is associated with greater PDGFR-β expression. Tailor et al reported that the IFP was higher in the high PDGFR-β group in nude mice bearing human non-small-cell lung cancer A549 xenografts (23) . Increased IFP acts as a barrier to drug distribution and the migration of cytotoxic T lymphocytes that target tumor cells (24) . High IFP is thus a prognostic factor of tumors. Yeo et al reported that IFP is a prognostic factor in patients with cervical cancer (25) . Milosevic et al (26) also showed that IFP is a predictor of survival in patients with cervical cancer. These findings suggest that reducing the IFP may contribute to improved survival. Pietras et al (27) demonstrated that the inhibition of PDGFR reduces the IFP and increases the capillary-to-interstitium transport of 51 Cr-EDTA in PROb rat colonic carcinomas. Pietras et al (28) also reported that the inhibition of PDGFR signaling enhances the antitumor effect of chemotherapy on subcutaneous KAT-4 tumors in FOX Chase severe combined immune deficiency mice. Emerich et al (29) showed that infusion of the bradykinin agonist Cereport (labradimil or RMP-7) in rats bearing experimental tumors reduces the IFP and increases deposition of [
14 C]-carboplatin in tumor tissue. These findings suggest that high PDGFR-β expression is associated with high IFP and causes resistance to chemotherapy by reducing blood flow to tumors and decreasing drug delivery in patients with gastric cancer after curative surgery and post-operative adjuvant chemotherapy with S-1. Imatinib is a PDGFR inhibitor. Wiig et al (30) reported that rats with colonic carcinomas treated with imatinib exhibited reduced IFP. Kim et al (24) demonstrated that treatment with imatinib markedly enhances the chemotherapeutic effects of antitumor drugs such as 5-fluorouracil and paclitaxel in vivo in gastric carcinoma MKN-45 cells transplanted into nude mice. These findings indirectly suggest that PDGFR-β expression may antagonize the antitumor effects of chemotherapy. However, further investigations are necessary to elucidate the underlying mechanisms.
In conclusion, PDGFR-β gene expression levels were higher in gastric cancer tissue than in adjacent normal mucosa in the present study, and the high expression of this gene was significantly associated with a poor outcome in patients with stage II/III gastric cancer who underwent curative resection and received adjuvant chemotherapy with S-1. These findings suggest that PDGFR-β overexpression is a useful, independent predictor of outcome in patients with stage II/III gastric cancer who receive curative surgery and post-operative adjuvant chemotherapy with S-1.
